logo
3 Growth Stocks to Buy and Forget About

3 Growth Stocks to Buy and Forget About

Globe and Mail4 hours ago
Key Points
AutoZone has delivered strong returns and continues to expand its business and store count.
Roku offers an early-stage growth opportunity in streaming and is still flying under the radar.
IBM is tapping into the AI boom and remains a solid pick for long-term investors.
Some investors trade often. Others take their time before pouncing on any particular stock, focusing on long-term investments they can just forget about for decades.
Imagine you're setting up a brand new portfolio for the long haul. Sure, you could stick with a tried and true S&P 500 index fund and call it a day, but you want to beat the market with this mini-portfolio. And it needs to be a low-effort activity, where you can forget about checking up on its stocks for decades -- and never lose a minute of sleep over their performance.
In this case, you should have a couple of clear objectives in mind:
Many years of longevity and business growth. A true long-term investment should still be relevant and thriving in a decade or three.
A competitive edge. Why settle for a decent performer in a strong industry when you can insist on top-shelf excellence?
A diverse group of stocks. The markets will ebb and flow over time, so your long-term investment bets should have distinctly different target markets. A focused artificial intelligence (AI) portfolio is one thing, and a broad basket of long-haul growth stocks is another.
So here are three growth stocks that meet all of these criteria. They are built to last, set up for long-lasting business growth, and leaders in their chosen fields. Together, their wide range of innovative operations should provide you with strong average returns across a wide range of stock market conditions.
Just buy them and jump in the lazy river, watch your kids grow up, or learn guitar over the next couple of decades. You won't have to worry about your growth stocks.
AutoZone's in the fast lane
Car parts retailer AutoZone (NYSE: AZO) is a surprising performer. The stock has gained 238% over the last 5 years and 16% in the first half of 2025. These are market-beating returns, comparable to fellow sector giant O'Reilly Automotive (NASDAQ: ORLY).
I wouldn't hate it if you picked O'Reilly instead of AutoZone, but this company has a couple of important advantages over the competition. First, the stock trades at significantly lower valuation multiples across the board. AutoZone also sports 12% higher annual revenues than O'Reilly, not to mention 8% richer bottom-line earnings. It even has an edge in long-term sales growth rates and a stronger balance sheet.
The company isn't sitting on its work-gloved hands, either. AutoZone is making heavy investments in a more capable supply chain, while also opening 84 net new stores in the recently reported Q3 of 2025.
And this happens to be a great time to stock up on shares in the retail sector. Many investors worry about tariffs and international conflicts, both of which can make consumers less likely to spend money. But I'm sure Americans will continue to fix and maintain their cars, regardless of the political climate. AutoZone should remain a leading name in that game for years and years, producing robust stock returns in the process.
Roku is my favorite media-streaming underdog
I keep coming back to Roku (NASDAQ: ROKU) when I'm looking for long-term growth stories. The media-streaming expert also happens to be undervalued most of the time, making it an easy pick in a crowded market.
Sure, I could have recommended Roku's former parent company Netflix (NASDAQ: NFLX) instead. Both companies are exploring a global media market with top-notch innovation under their belts and promising growth trends. But Roku is at an earlier stage of its international growth story, with so much untapped market value left to grab. Netflix is far from stalled out -- but Roku is just getting started. This is the more exciting growth story today.
The company is currently unprofitable, but that's by design. Roku's management is throwing everything but the kitchen sink at the company's growth opportunities, investing in everything from original content to powerful advertising platforms. The stock has been disappointing in recent years, but I see the downtrend as a wide-open buying window. If Roku isn't beating the market by 2035, I'll buy a hat just to eat it. Hold the salt, please.
IBM proves that old dogs really can learn new AI tricks
Finally, let's tap into the unstoppable generative AI boom. IBM (NYSE: IBM) may not strike you as a leader in that jam-packed industry, but that's a mistake. Big Blue is simply going after a different customer population than its headline-writing AI peers. As always, IBM is all about business-class services for enterprise customers. It's a massive target market, IBM's long-term AI focus is starting to pay off right now, and the stock looks dirt cheap anyhow.
IBM shares are changing hands at the affordable price of 4.3 times sales or 21.5 times free cash flows. If IBM were a part of the "Magnificent Seven" group, it would be the lowest-priced option in terms of cash flow-based valuations.
Plus, this company wrote the book on business longevity. IBM was founded more than a century ago, thriving despite a couple of world wars and a variety of economic crises. Big Blue should be the first place to look when you're on the hunt for long-term investment ideas.
Should you invest $1,000 in Roku right now?
Before you buy stock in Roku, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Roku wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!*
Now, it's worth noting Stock Advisor 's total average return is1,060% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 30, 2025
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Iovance Biotherapeutics CFO Resignation and Interim Appointment
Iovance Biotherapeutics CFO Resignation and Interim Appointment

Globe and Mail

time36 minutes ago

  • Globe and Mail

Iovance Biotherapeutics CFO Resignation and Interim Appointment

Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Iovance Biotherapeutics ( (IOVA)) just unveiled an announcement. On June 30, 2025, Iovance Biotherapeutics announced the resignation of Jean-Marc Bellemin as Chief Financial Officer, effective immediately, with Matthew W. Rosinack stepping in as interim Principal Financial Officer and Principal Accounting Officer. Rosinack, who has extensive experience in finance roles at various biotechnology and medical device companies, has been with Iovance since September 2021 and will temporarily fill the role as the company navigates this transition. The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page. Spark's Take on IOVA Stock According to Spark, TipRanks' AI Analyst, IOVA is a Neutral. Iovance Biotherapeutics' stock score reflects its current growth phase marked by significant revenue increases and strong equity, offset by ongoing losses and cash flow challenges. The technical indicators suggest bearish momentum, while mixed earnings call sentiments and recent corporate events add moderate risk. The valuation is impacted by negative earnings, typical for a company investing heavily in growth. To see Spark's full report on IOVA stock, click here. More about Iovance Biotherapeutics Average Trading Volume: 13,697,268 Technical Sentiment Signal: Sell Current Market Cap: $581M See more data about IOVA stock on TipRanks' Stock Analysis page. Disclaimer & Disclosure Report an Issue

Point of Care Diagnostics Market to Hit USD 22.63 Billion by 2029 with 8.5% CAGR
Point of Care Diagnostics Market to Hit USD 22.63 Billion by 2029 with 8.5% CAGR

Globe and Mail

time36 minutes ago

  • Globe and Mail

Point of Care Diagnostics Market to Hit USD 22.63 Billion by 2029 with 8.5% CAGR

"The major players operating in this market are Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMérieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK)" Browse 786 market data Tables and 64 Figures spread through 577 Pages and in-depth TOC on "Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (TB, HAI, STD), Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx (RT-PCR, INAAT)), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2029 The global point of care diagnostics market valued at US$ 14.26 billion in 2023, is forecasted to grow at a robust CAGR of 8.5%, reaching US$ 15.05 billion in 2024 and an impressive US$ 22.63 billion by 2029. The growing prevalence of chronic diseases, such as diabetes has necessitated a need for routine monitoring with early and timely detection. Since these conditions need to be constantly monitored, the demand for quick, effective, and appropriate testing methods have expanded. For instance, increasing demand for POC diagnostics like glucose monitoring products is because of the easy, quick results, which patients get, helping them to take care of the disease and make an early intervention. Government initiatives promoting POC testing, including investments in health care innovation are also contributing to increased market growth. Browse in-depth TOC on " Point of Care Diagnostics Market" 778 - Tables 59 - Figures 564 - Pages Advances such as miniaturized, transportable diagnostic devices, which present laboratory-quality findings outside of health care settings, represent a leading technological shift within the point of care diagnostics market. These small devices, largely based on new, advanced forms of biosensors, will deliver testing in real-time with higher degrees of accuracy at a faster cost and are sure to revolutionize health care. These will affect health care primarily in areas related to conditions whose management requires routine monitoring, which includes diabetes and infectious diseases. As these devices continue to become increasingly accessible and affordable, they are going to create new business opportunities in home healthcare, telemedicine, and emergency care, and accelerating adoption across all patient populations. Based on mode of purchase, the point of care diagnostics market is segmented into OTC testing products and prescription-based testing products. The prescription-based testing products segment is expected to be the fastest-growing segment in the market. Stricter regulatory standards, focus on quality, and healthcare providers' recommendation for the test are among the key factors that contribute to the high growth rate of prescription-based testing products. These products need to be subjected to very strict quality and safety measures, which improves the credibility and reliability of these products. Healthcare providers actively engage in using these tests in a way that they produce the best clinical results. With the focus on early detection, prescription-based testing continues to experience strong market growth, which is driving its high growth rate. Categorized by technology, the point of care diagnostics market is segmented into immunoassays, molecular diagnostics, and biochemistry. The biochemistry segment is the dominant technology segment because these tests can quickly, reliably, and cost-effectively provide the results for conditions such as diabetes and pregnancy & fertility testing. Real-time results offered by biochemistry-based tests, like glucose meters are easy to use and well-suited both for homecare and emergency applications. Such technologies assure on-site diagnosis without the complexity of expensive laboratory infrastructure in a point of care environment. With such convenience, accessibility, and ability to cater to increasing demands for rapid and efficient testing, biochemistry technology continues to lead the market. The key players in this market are Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMérieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK), Trinity Biotech (Ireland), Werfen (US), Nova Biomedical (US), SEKISUI Diagnostics (US), and Boditech Med Inc. (South Korea). The market players have adopted various strategies such as development of advanced products, partnerships, expansions, and acquisitions to strengthen their position in the point of care diagnostics market. The organic and inorganic strategies have helped the market players expand globally by providing advanced point of care tests. Abbott is a key player in the point of care diagnostics market, offering a comprehensive range of diagnostic solutions such as blood screening, immunoassays, and clinical chemistry systems. The company's strong global presence allows it to expand its reach in both established and emerging markets. Abbott stays ahead of the competition through continuous innovation and a focus on research and development. By introducing new products and securing important regulatory approvals, Abbott has solidified its leadership. For example, in April 2024, the company's i-STAT TBI cartridge received FDA clearance to be used with whole blood, further strengthening its position in the POC diagnostics market. F. Hoffmann-La Roche Ltd is a major player in the global point of care diagnostics market, having gained a reputation as a leader in the diagnostics market. Its extensive portfolio and global presence have enabled the company to maintain its competitive edge. Roche has an excellent direct and indirect distribution network across the world, which allows it to compensate for demand volatility in the various markets. Its strategic focus both on organic and inorganic growth strategies further strengthens the company's market presence. For instance, the cobas pulse system was launched by Roche in January 2022 as a connected point-of-care solution to be used with professional blood glucose monitoring only in certain CE Mark countries. All these strategies, along with its strong presence in the market, have given Roche further opportunities to enhance its position within the point of care diagnostics market. Siemens Healthineers AG is a leading company in the point of care diagnostics market, providing a broad range of products like clinical chemistry platforms, immunodiagnostics, and molecular diagnostic testing. The company is committed to expanding its portfolio through strategic acquisitions and innovations in order to respond to the changing needs of patients and healthcare providers. Moreover, Siemens Healthineers focuses on partnerships to further strengthen its position in the market. With a significant worldwide presence in over 70 countries, the group is poised well for growth in the POC diagnostics market. For more information, Inquire Now!

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store